AU2019392908B2 - Methods for treating cancer in models harboring ESR1 mutations - Google Patents

Methods for treating cancer in models harboring ESR1 mutations Download PDF

Info

Publication number
AU2019392908B2
AU2019392908B2 AU2019392908A AU2019392908A AU2019392908B2 AU 2019392908 B2 AU2019392908 B2 AU 2019392908B2 AU 2019392908 A AU2019392908 A AU 2019392908A AU 2019392908 A AU2019392908 A AU 2019392908A AU 2019392908 B2 AU2019392908 B2 AU 2019392908B2
Authority
AU
Australia
Prior art keywords
elacestrant
subject
cancer
fulvestrant
estrogen receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019392908A
Other languages
English (en)
Other versions
AU2019392908A1 (en
Inventor
Heike ARLT
Teeru BIHANI
Hitisha PATEL
Nianjun Tao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Radius Pharmaceuticals Inc
Original Assignee
Radius Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Radius Pharmaceuticals Inc filed Critical Radius Pharmaceuticals Inc
Publication of AU2019392908A1 publication Critical patent/AU2019392908A1/en
Application granted granted Critical
Publication of AU2019392908B2 publication Critical patent/AU2019392908B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2019392908A 2018-12-06 2019-12-06 Methods for treating cancer in models harboring ESR1 mutations Active AU2019392908B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862776338P 2018-12-06 2018-12-06
US62/776,338 2018-12-06
PCT/US2019/064980 WO2020118202A1 (en) 2018-12-06 2019-12-06 Methods for treating cancer in models harboring esr1 mutations

Publications (2)

Publication Number Publication Date
AU2019392908A1 AU2019392908A1 (en) 2021-06-10
AU2019392908B2 true AU2019392908B2 (en) 2025-02-20

Family

ID=69158304

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019392908A Active AU2019392908B2 (en) 2018-12-06 2019-12-06 Methods for treating cancer in models harboring ESR1 mutations

Country Status (17)

Country Link
US (2) US20220016052A1 (enExample)
EP (1) EP3890835A1 (enExample)
JP (2) JP7497353B2 (enExample)
KR (1) KR20210100135A (enExample)
AU (1) AU2019392908B2 (enExample)
BR (1) BR112021010141A2 (enExample)
CA (1) CA3121918A1 (enExample)
EA (1) EA202191256A1 (enExample)
IL (1) IL283655A (enExample)
JO (1) JOP20210138A1 (enExample)
MA (1) MA54393A (enExample)
MX (1) MX2021006412A (enExample)
MY (1) MY208702A (enExample)
PH (1) PH12021551327A1 (enExample)
SG (1) SG11202105915UA (enExample)
UA (1) UA129588C2 (enExample)
WO (1) WO2020118202A1 (enExample)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180153828A1 (en) * 2015-04-29 2018-06-07 Radius Pharmaceuticals, Inc. Methods for treating cancer

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI3834824T3 (fi) * 2014-03-28 2025-12-05 Univ Duke Estrogeenireseptoripositiivisen rintasyövän hoito selektiivisellä estrogeenireseptorin modulaattorilla

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180153828A1 (en) * 2015-04-29 2018-06-07 Radius Pharmaceuticals, Inc. Methods for treating cancer

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
FANNING et al.: "Estrogen receptor alpha somatic mutations Y537S and D538G confer breast cancer endocrine resistance by stabilizing the activating function-2 binding conformation", ELIFE, vol. 5, 2016, pages 1 - 25 *
REINERT T. et al.: "Implications of ESR1 Mutations in Hormone Receptor-Positive Breast Cancer", CURRENT TREATMENT OPTIONS IN ONCOLOGY, vol. 19, no. 5, 17 April 2018, pages 1 - 13, DOI: 10.1007/S11864-018-0542-0 *
TEERU BIHANI et al.: "Elacestrant (RAD1901), a Selective Estrogen Receptor Degrader (SERD), Has Antitumor Activity in Multiple ER + Breast Cancer Patient-derived Xenograft Models", CLINICAL CANCER RESEARCH, v23, n16, 2017, pp. 4793-4804 *

Also Published As

Publication number Publication date
CA3121918A1 (en) 2020-06-11
EA202191256A1 (ru) 2021-10-06
KR20210100135A (ko) 2021-08-13
MA54393A (fr) 2021-10-13
PH12021551327A1 (en) 2022-04-25
IL283655A (en) 2021-07-29
JP2022511497A (ja) 2022-01-31
JP2024101017A (ja) 2024-07-26
WO2020118202A1 (en) 2020-06-11
EP3890835A1 (en) 2021-10-13
BR112021010141A2 (pt) 2021-08-24
JP7497353B2 (ja) 2024-06-10
AU2019392908A1 (en) 2021-06-10
US20250241875A1 (en) 2025-07-31
MY208702A (en) 2025-05-25
UA129588C2 (uk) 2025-06-11
SG11202105915UA (en) 2021-07-29
US20220016052A1 (en) 2022-01-20
MX2021006412A (es) 2021-07-21
JOP20210138A1 (ar) 2023-01-30

Similar Documents

Publication Publication Date Title
US20220339126A1 (en) Methods for treating cancer
US20250319044A1 (en) Methods for treating cancer resistant to cdk4/6 inhibitors
AU2019392908B2 (en) Methods for treating cancer in models harboring ESR1 mutations
RU2822195C2 (ru) Способы лечения рака на моделях, имеющих мутации esr1
EA046925B1 (ru) Способы лечения рака на моделях, имеющих мутации esr1
HK40079056A (en) Methods of treating cancer

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)